NCT01942005

EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients

EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 144 (actual)
• Sponsor: Andreas Arnold · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Detailed description

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Conditions

• Immunosuppression
• Neoplasm

Timeline

• Start date: 2010-01-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2013-09-13
• Last updated: 2014-12-04

Locations

1 site across 1 country: Switzerland